ReviewJournal of Cancer2026
The Role of Lipid Metabolism in the Progression of Breast Cancer.
Review in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most prevalent malignancies globally, it is closely associated with lipid metabolism reprogramming. Targeting lipid metabolism pathways has become a promising strategy for breast cancer treatment. Lipid metabolism encompasses the biochemical processes of lipid biosynthesis, catabolism, uptake, and post-synthetic modification. Dysregulation of these processes can promote tumorigenesis and cancer cell metastasis. This review summarizes four major facets of lipid metabolism, including fatty acid (FA) metabolism, cholesterol metabolism, phospholipid (PL) metabolism, and sphingolipid metabolism. It also discusses the roles of key molecules in these pathways in breast cancer, including FA synthase (FASN), cluster of differentiation 36 (CD36), and acyl-CoA synthetase long-chain family member 4 (ACSL4). These molecules may improve therapeutic responses, overcome drug resistance, and reshape the tumor immune microenvironment by regulating FA synthesis and lipid uptake. Targeting lipid metabolic pathways may provide potential biomarkers for patient stratification and therapeutic guidance, and may also offer new opportunities for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.